Navitoclax

2 trials Orphan designation

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

0 Recruiting

2 Completed trials

1 Sponsors

7 Countries

Phase II

Phase I (Other)

Phase II: 1 Phase I (Other): 1

Indications tested

Myelofibrosis 1 Myeloproliferative neoplasm 1

Sponsors using this IMP

AbbVie Deutschland GmbH & Co. KG 2

All trials

2 total

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Participants Wit… Ended

2023-507274-40-00 Phase I (Other) 6 countries AbbVie Deutschland GmbH & Co. KG
A Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax alone or in Combination with Ruxolitinib in Subjects with Myelofibrosi… Ended

2023-507276-53-00 Phase II 4 countries AbbVie Deutschland GmbH & Co. KG

Showing 1–2 of 2 trials

← All drugs A–Z